Switch theme
Sign up to access all valuation multiples
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
1941
10.7K+
LTM Revenue $5.4B
LTM EBITDA $655M
$7.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eisai Co. has a last 12-month revenue (LTM) of $5.4B and a last 12-month EBITDA of $655M.
In the most recent fiscal year, Eisai Co. achieved revenue of $5.1B and an EBITDA of $711M.
Eisai Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eisai Co. valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.4B | XXX | $5.1B | XXX | XXX | XXX |
| Gross Profit | $4.3B | XXX | $4.0B | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $655M | XXX | $711M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $377M | XXX | $367M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $318M | XXX | $291M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Eisai Co.'s stock price is JPY 4141 (or $28).
Eisai Co. has current market cap of JPY 1.17T (or $8.0B), and EV of JPY 1.09T (or $7.5B).
See Eisai Co. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.5B | $8.0B | XXX | XXX | XXX | XXX | $1.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Eisai Co. has market cap of $8.0B and EV of $7.5B.
Eisai Co.'s trades at 1.5x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate Eisai Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eisai Co. has a P/E ratio of 25.2x.
See valuation multiples for Eisai Co. and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.0B | XXX | $8.0B | XXX | XXX | XXX |
| EV (current) | $7.5B | XXX | $7.5B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 19.8x | XXX | 21.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.2x | XXX | 25.6x | XXX | XXX | XXX |
| EV/FCF | 44.0x | XXX | 76.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEisai Co.'s last 12 month revenue growth is 2%
Eisai Co.'s revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Eisai Co.'s rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eisai Co.'s rule of X is 17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eisai Co. and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 16% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eisai Co. acquired XXX companies to date.
Last acquisition by Eisai Co. was XXXXXXXX, XXXXX XXXXX XXXXXX . Eisai Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Eisai Co. founded? | Eisai Co. was founded in 1941. |
| Where is Eisai Co. headquartered? | Eisai Co. is headquartered in Japan. |
| How many employees does Eisai Co. have? | As of today, Eisai Co. has 10.7K+ employees. |
| Who is the CEO of Eisai Co.? | Eisai Co.'s CEO is Mr. Haruo Naito. |
| Is Eisai Co. publicy listed? | Yes, Eisai Co. is a public company listed on TKS. |
| What is the stock symbol of Eisai Co.? | Eisai Co. trades under 4523 ticker. |
| When did Eisai Co. go public? | Eisai Co. went public in 1961. |
| Who are competitors of Eisai Co.? | Similar companies to Eisai Co. include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Eisai Co.? | Eisai Co.'s current market cap is $8.0B |
| What is the current revenue of Eisai Co.? | Eisai Co.'s last 12 months revenue is $5.4B. |
| What is the current revenue growth of Eisai Co.? | Eisai Co. revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Eisai Co.? | Current revenue multiple of Eisai Co. is 1.4x. |
| Is Eisai Co. profitable? | Yes, Eisai Co. is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eisai Co.? | Eisai Co.'s last 12 months EBITDA is $655M. |
| What is Eisai Co.'s EBITDA margin? | Eisai Co.'s last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Eisai Co.? | Current EBITDA multiple of Eisai Co. is 11.4x. |
| What is the current FCF of Eisai Co.? | Eisai Co.'s last 12 months FCF is $170M. |
| What is Eisai Co.'s FCF margin? | Eisai Co.'s last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Eisai Co.? | Current FCF multiple of Eisai Co. is 44.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
